Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel

Norbert Kovács*, Lars Bergmann, Marieta Anca-Herschkovitsch, Esther Cubo, Thomas L. Davis, Robert Iansek, Mustafa S. Siddiqui, Mihaela Simu, David G. Standaert, K. Ray Chaudhuri, Paul Bourgeois, Tianming Gao, Pavnit Kukreja, Francesco E. Pontieri, Jason Aldred

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Background: It is believed that motor symptoms, including dyskinesia, and non-motor symptoms impact health-related quality of life (HRQoL) in patients with Parkinson's disease (PD), and that improvements in these metrics are correlated. Objective: Investigate the relationship between HRQoL and measures of PD severity and treatment efficacy, including motor and non-motor symptoms. Methods: This was a planned investigation of an international, prospective, single-arm, post-marketing observational study of the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD. Pearson correlation coefficients (PCC) were calculated for baseline and change from baseline at 12 months between HRQoL and motor and non-motor symptoms. Results: A total of 195 patients were included. At baseline, HRQoL was moderately positively correlated with Activities of Daily Living (UPDRS II, PCC = 0.44), non-motor symptoms (0.48), and measures of sleep (0.50 and 0.40); all p < 0.001. After 12 months of treatment with LCIG, improvements in HRQoL were moderately positively correlated with improvement from baseline in non-motor symptoms (PCC = 0.42), sleep (0.54), and daytime sleepiness (0.40; all p < 0.001), and weakly correlated with improvement in dyskinesia signs and symptoms (PCC = 0.23; p = 0.011). Improvement in HRQoL was not correlated with improvements in OFF time or dyskinesia time. Conclusion: Both at baseline and for change from baseline at 12 months, HRQoL was correlated with baseline and change from baseline in dyskinesia, Activities of Daily Living, and non-motor symptoms, including sleep; but not with baseline or change in OFF time.

Original languageEnglish
Pages (from-to)917-926
Number of pages10
JournalJournal of Parkinson's Disease
Volume12
Issue number3
DOIs
Publication statusPublished - 5 Apr 2022

Keywords

  • Dyskinesia
  • health-related quality of life
  • levodopa-carbidopa intestinal gel
  • non-motor symptoms
  • Parkinson's disease

Fingerprint

Dive into the research topics of 'Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel'. Together they form a unique fingerprint.

Cite this